Summary
51 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 325% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- Out of every 100 SGD of revenue, 6.9 SGD is left as free cash.
What to watch
- It pays out more in dividends than it earns: 264% of profit.
- Repaying its net debt would take 5.7 years of operating profit.
- Revenue growth is slowing: 4.3% a year over the last 3 years against 8.7% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 32.6 SGD for 1 SGD of yearly profit. Over the last five years it was 47.8 SGD on average.
Valuation in detailIs it growing?
SlowlyRevenue (SGD)
Diluted EPS (SGD)
- Analyst estimate
Revenue grew by 8.7% a year over 5 years. Over the last 3 years it grew by 4.3% a year. Earnings per share grew by 325% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 SGD of revenue goes
- Cost of sales 49 SGD
- Sales and administration 24 SGD
- Taxes and other 24 SGD
- Net profit 3.6 SGD
Net profit, industry median (Chemicals - Specialty) 6.1 SGD
Out of every 100 SGD of revenue, 3.6 SGD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 20.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 8.08%
- Paid out of profit
- 264%
- Raised in a row
- 1 year
You receive $0.04 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail